Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus (NYSE: BVS) is a global medical device company specializing in orthobiologics and regenerative medicine solutions aimed at enhancing bone healing and joint health. Founded in 2012 and headquartered in Durham, North Carolina, the company develops and markets products that support non‐surgical and minimally invasive treatment options for patients suffering from musculoskeletal injuries and conditions. Bioventus has built a reputation for innovation by leveraging proprietary technologies and clinical evidence to advance patient outcomes across a range of indications.

The company’s core product portfolio includes EXOGEN®, a low‐intensity pulsed ultrasound system designed to accelerate fracture healing, and HYLAURONATE injectable therapies such as Durolane® and MONOVISC®, which are used for viscosupplementation in osteoarthritis of the knee. These offerings are complemented by a robust research and development pipeline focused on novel delivery mechanisms, biologic agents, and next‐generation formulations. Bioventus emphasizes evidence‐based practice, supporting its products with extensive clinical studies and peer‐reviewed publications.

Bioventus operates across North America, Europe, Asia Pacific and select emerging markets through direct sales forces, distribution partners, and strategic alliances. Its products are utilized in hospitals, outpatient surgery centers and physician offices, enabling access to treatments for orthopedic surgeons, sports medicine physicians and podiatrists. The company also maintains a global logistics and support network to ensure timely product availability and training for healthcare professionals.

Under the leadership of a seasoned management team with deep expertise in the medical device and regenerative medicine industries, Bioventus continues to pursue strategic acquisitions and partnerships to broaden its clinical offerings and geographic reach. The company remains committed to its mission of making faster physical recovery a reality for patients worldwide through the development of scientifically validated, non‐opioid solutions that address pain, inflammation and tissue healing.

Key Stats

• Today's Range: $6.87 to $7.32
• 50-Day Range: $6.20 to $7.39
• 52-Week Range: $6.02 to $14.38
• Volume: 402,711 shs
• Average Volume: 428,839 shs
• Market Capitalization: $572.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.75
• Consensus Rating: Moderate Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 60% of companies evaluated by MarketBeat, and ranked 364th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Bioventus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.20%

Earnings Growth

Earnings for Bioventus are expected to grow by 12.20% in the coming year, from $0.41 to $0.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is -11.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is -11.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BVS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BVS.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.27

News Sentiment

Bioventus has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Bioventus this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.00% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BVS Stock Analysis - Frequently Asked Questions

How have BVS shares performed this year?

Bioventus' stock was trading at $10.50 at the beginning of the year. Since then, BVS shares have decreased by 33.6% and is now trading at $6.97.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) released its quarterly earnings results on Tuesday, November, 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The business earned $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

Who are Bioventus' major shareholders?

Top institutional investors of Bioventus include Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, Mark Leonard Singleton, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali.
View institutional ownership trends.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioventus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:BVS
• CIK: 1665988
• Web: www.bioventus.com
• Phone: 919-474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bioventus: $13.75
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +97.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 17.00
• P/E Growth: N/A
• Net Income: -$156.23 million
• Net Margins: -7.11%
• Pretax Margin: -10.41%
• Return on Equity: 15.61%
• Return on Assets: 4.01%

Debt

• Debt-to-Equity Ratio: 1.85
• Current Ratio: 1.41
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $567.70 million
• Price / Sales: 1.01
• Cash Flow: $0.55 per share
• Price / Cash Flow: 12.58
• Book Value: $2.80 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 82,144,000
• Free Float: 54,455,000
• Market Cap: $572.54 million
• Optionable: Not Optionable
• Beta: 0.84